Galecto, Inc. (GLTO)
NASDAQ: GLTO · Real-Time Price · USD
6.73
-0.10 (-1.46%)
Nov 4, 2024, 4:00 PM EST - Market closed
Galecto Employees
Galecto had 13 employees as of December 31, 2023. The number of employees decreased by 32 or -71.11% compared to the previous year.
Employees
13
Change (1Y)
-32
Growth (1Y)
-71.11%
Revenue / Employee
n/a
Profits / Employee
-$1,628,692
Market Cap
7.30M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 13 | -32 | -71.11% |
Dec 31, 2022 | 45 | 5 | 12.50% |
Dec 31, 2021 | 40 | 12 | 42.86% |
Dec 31, 2020 | 28 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Syra Health | 162 |
Zhongchao | 142 |
Viracta Therapeutics | 40 |
Aptose Biosciences | 36 |
Healthcare Triangle | 31 |
Organovo Holdings | 20 |
Moleculin Biotech | 18 |
Alzamend Neuro | 7 |
GLTO News
- 3 days ago - Galecto Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 20 days ago - Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler - GlobeNewsWire
- 4 weeks ago - Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines - GlobeNewsWire
- 2 months ago - Galecto Announces Reverse Stock Split - GlobeNewsWire
- 6 months ago - Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab - GlobeNewsWire
- 11 months ago - Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis - GlobeNewsWire
- 1 year ago - Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial - GlobeNewsWire
- 1 year ago - Galecto Announces Plans to Explore Strategic Alternatives - GlobeNewsWire